MabThera nabs NICE nod for leukemia

The U.K.'s cost-effectiveness watchdog has recommended Roche's top-selling cancer drug MabThera as a first line treatment for the most common form of adult leukemia. NICE recommends that the National Health Service pay for MabThera treatment only in combination with two specific chemo drugs. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.